Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

HAYWARD, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented updated data from a dose-escalating Phase 1b clinical trial of Hsp90 inhibitor tanespimycin (KOS-953) in combination with bortezomib (Velcade(R)), showing durable antitumor activity and tolerability in patients with multiple myeloma who had previously progressed following treatment with multiple conventional therapies. The data presentation includes summary aggregate results from patients treated with all doses of Kosan's prior Cremophor-containing formulation and with Kosan's new injectable suspension formulation. Responses were seen across dose levels in the bortezomib-naive, pre-treated and refractory patients. Both formulations demonstrated activity, and the combination was manageable relative to safety, with no Grade 3 neurotoxicity to date. This finding supports the potential neuroprotective effect of tanespimycin. The data were presented on Saturday, December 8, 2007, by Paul Richardson, M.D., Department of Hematology, Dana Farber Cancer Center, Boston, MA, in a poster titled "Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation," at the 2007 Annual Meeting of the American Society of Hematology (ASH).

"Tanespimycin continues to be of interest as a potential treatment for patients with multiple myeloma who have failed prior regimens due to its tolerability and potential for additive or synergistic activity with bortezomib," said Kenneth C. Anderson, M.D., Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, senior author on the poster. "The new injectable suspension formulation appears to be
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  This year alone, The ... 300 research projects with one goal in mind: Discovering ... "Team In Training" (TNT), a flagship LLS fundraising campaign ... program, is marking its landmark 25 th anniversary. ... $875 million in research to discover and deliver breakthrough ...
(Date:6/19/2013)... , June 19, 2013 Today MedeAnalytics, ... introduced the next-generation of its Employer Group ... health plans to provide their employer groups an ... factors, medical and prescription drug claims, network utilization, ... http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer Group ...
(Date:6/18/2013)... MILAN , June 19, 2013 ... in fluctuating Parkinson,s disease (PD) patients as add-on ... clinically important improvement in motor symptoms in fluctuating ...   Newron Pharmaceuticals S.p.A. ("Newron"), a ... and pain therapies, and its partner Zambon S.p.A., ...
Breaking Medicine Technology:Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6
... 2011 Asante Solutions, Inc. (Asante), a medical device ... the CE mark for its Pearl Insulin Pump, the ... The CE mark is a European proof of conformity ... environmental requirements. Asante has begun discussions with potential distribution ...
... 12, 2011 PRA International, a leading Clinical Research Organization, ... (SRM) group will speak at the World Drug Safety Congress ... will also host an exhibit at booth #2. ... chair the first breakout stream, "Operational Safety," on 13 April ...
Cached Medicine Technology:Asante Solutions, Inc. Receives CE Mark for Pearl™ Insulin Pump 2PRA International Experts to Speak at Drug Safety Conference 2
(Date:6/19/2013)... years, Alzheimer,s researchers have focused on two proteins that ... may contribute to the disease: plaques made up of ... tau. , But for the first time, an Alzheimer,s ... independently, but at the interaction of the two proteins ... post-mortem Alzheimer,s patients and in mouse brains with Alzheimer,s ...
(Date:6/19/2013)... that the incidence of cancer is many fold higher ... have an inadequate understanding on how best to treat ... are occasionally included in clinical trials, those elderly patients ... patients. Thus, the broader elderly patient population is not ... the Elderly Task Force is now starting a new ...
(Date:6/19/2013)... IL (PRWEB) June 19, 2013 Chicago is ... the 31st, 48th and 50th Chicago Wards will require landlords ... – or face fines. The ordinance also makes ... complying with all treatment requests – which often include disposing ... pest control company Orkin reported that it did more bed ...
(Date:6/19/2013)... The Cancer Support Community (CSC), an international nonprofit organization, ... whole patient with the launch today of the Cancer ... event, held at the Newseum, will feature a keynote ... members who have made a significant impact on cancer ... engaged in the cancer journey. , ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 A brain ... for those closest to them. The sudden onset of ... brain tumor has on a patient’s behavioral and cognitive ... both the patient and family. The American Brain ... July 26 and Saturday, July 27 in Chicago, focuses ...
Breaking Medicine News(10 mins):Health News:New Alzheimer's research suggests possible cause: The interaction of proteins in the brain 2Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Chicago Ordinance Requires Landlords and Tenants to Take Responsibility for Bed Bugs 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 2Health News:Keeping the Promise of Cancer Care for the Whole Patient 3Health News:American Brain Tumor Association Conference Advances Holistic Approach to Living with a Brain Tumor 2Health News:American Brain Tumor Association Conference Advances Holistic Approach to Living with a Brain Tumor 3
... 2, 2010 As part of a national clinical ... in effectiveness between two popular treatments for one of ... incontinence. Stress incontinence affects up to 50 percent ... their lives. Women with stress incontinence experience leakage during ...
... PeriGen, ... clinical and financial value, today announced that Donald A. Deieso, Ph.D., the Company’s Chairman ... 2010 Award in New Jersey. , ... Princeton, NJ -- PeriGen, Inc. , the only OB-specific risk ...
... has received the human papillomavirus (HPV) vaccine to help prevent ... Washington University School of Medicine in St. Louis. The ... American Journal of Preventive Medicine . The HPV vaccine ... of which are found in about 70 percent of all ...
... Healthcare reform -- and the many options for fixing a broken ... According to an article in the June issue of the ... many who suffer from disabling arthritis of the hip and knee, ... crisis to medical care. "This is not a just a ...
... if young adults were more fit, 34% of high blood ... News) -- Low levels of physical activity and fitness significantly ... study of young adults shows. , The study, released online ... issue of the journal Hypertension , found that about ...
... have paired up to create technology that has ... the first procedure-based, hands-on surgical training software. Their ... surgeons through real-time operative procedures using the Robotic ... MD, a staff physician in Urology at Roswell ...
Cached Medicine News:Health News:UT Southwestern investigators perform head-to-head comparison of incontinence treatments 2Health News:Donald A. Deieso, Ph.D., Chairman & CEO, PeriGen, Inc. Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist 2Health News:Donald A. Deieso, Ph.D., Chairman & CEO, PeriGen, Inc. Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist 3Health News:One-third of young girls get HPV vaccine to prevent cervical cancer 2Health News:One-third of young girls get HPV vaccine to prevent cervical cancer 3Health News:Health-care economics and policy: It's a perfect storm 2Health News:Health-care economics and policy: It's a perfect storm 3Health News:Being Young and Sedentary Raises Hypertension Risk Later 2Health News:Being Young and Sedentary Raises Hypertension Risk Later 3Health News:Surgeon-engineer team produce training software for robot-assisted surgery 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: